Key Highlights

  • CEL-SCI Corporation announces a stock offering of up to 2,500,000 shares.
  • The shares are offered at a price of $1.00 per share.
  • ThinkEquity will serve as the exclusive placement agent for the offering.
  • Compensation to ThinkEquity includes a cash fee of 7% of the aggregate purchase price.
  • The offering is expected to close on June 16, 2026.

CEL-SCI Corporation (NYSE: CVM) has formalized a Placement Agency Agreement with ThinkEquity LLC, positioning the company to conduct a significant stock offering.

This initiative, announced on June 14, 2026, allows CEL-SCI to issue approximately 2,500,000 shares of its common stock at a set price of $1.00 per share.

ThinkEquity is appointed as the exclusive placement agent in this transaction, tasked with facilitating connections with potential investors.

Unlike traditional underwriters, ThinkEquity will operate on a "reasonable best efforts” basis, emphasizing its role in reaching out to various investors without guaranteed purchase commitments.

The compensation structure for ThinkEquity includes a notable cash fee, constituting 7% of the total purchase price paid by the investors.

This fee reduces the proceeds that CEL-SCI will ultimately receive but aligns the interests of the placement agent with the successful completion of the offering.

The closing of this stock offering is scheduled for June 16, 2026, with the funds anticipated to further bolster CEL-SCI’s financial strategy.

The company underscores that the offering is independently assessed and represented as an arm’s-length transaction, highlighting the non-fiduciary relationship between itself and ThinkEquity.

By availing this financing mechanism, CEL-SCI aims to enhance its operational capabilities and accelerate growth initiatives.

As part of compliance with regulatory requirements, CEL-SCI has prepared a registration statement with the U.S.

Securities and Exchange Commission under the Securities Act of 1933.

This registration statement plays a crucial role in ensuring that the offering adheres to legal stipulations while maintaining transparency with potential investors.

As the market reacts, investors will likely scrutinize CEL-SCI’s use of the proceeds from this offering, which could drive future valuation metrics.

Anticipation around the funds can influence trading dynamics leading up to the closing date and beyond.

Overall, this agreement reflects a strategic move by CEL-SCI Corporation to enhance liquidity and support ongoing business initiatives in a challenging economic environment.

The collaboration with ThinkEquity may set a precedent for how CEL-SCI approaches future capital-raising efforts, enhancing its position within the competitive healthcare sector.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.